The BIOMAP consortium has published a paper in the British Journal of Dermatology studying measurable predictors (biomarkers) linked with safe and effective response to treatment in psoriasis.
What is a biomarker?
According to the Biomap consortium “Biomarkers are molecules that naturally exist within the human body and are often present at different levels in people who do not respond well to particular a treatment.”
What is psoriasis?
Psoriasis is a common inflammatory skin condition that affects more than 73,000 people in Ireland. The main symptoms of psoriasis are red raised patches which can be sometimes covered with a silvery white scale, also known as plaques, which can make the skin dry, itchy and sometimes flake. Common sites where psoriasis can occur include, scalp, lower back, and knees and elbows. However, any skin surface and nails can be affected by psoriasis.
What causes psoriasis?
The exact cause is not completely understood, but genetics and the immune system are important in its development. Psoriasis can also be triggered or aggravated in those who are susceptible by several factors. In some cases, emotional stress, infection (such as streptococcal throat infection), injury to the skin, certain medications, and certain lifestyle factors such as drinking too much alcohol and smoking may worsen it.
Related: The ISF psoriasis information webpage
Related: The ISF booklet what you need to know about psoriasis.
Related: Biomap project
What is the aim of this Biomap study?
Treatment of psoriasis depends on its severity and location, and can range from topical treatments and phototherapy, to systemic agents (tablet or injection). Recent advances in systemic treatments for psoriasis have improved the lives of people living with moderate-severe psoriasis. However for some, their response has been varied and less effective. The Biomap consortium performed a scoping review to identify biomarkers linked with a less effective response or adverse events in systemic treatments used for psoriasis.
“71 studies were identified, investigating biomarkers linked with a less effective response or adverse events to tablet or injectable treatments used for psoriasis.” (BIOMAP consortium)
To read the lay summary and findings of this piece of research by Biomap, click here
If you need help or guidance about managing your psoriasis, contact the ISF Helpline here.